Blog
SS-31: a phase 3 trial that missed its primary endpoints
Elamipretide is commonly discussed as SS-31. This trial tests clinical outcomes rather than mitochondrial mechanisms alone, and its negative primary findings should remain prominent.
Evidence discussed: Randomized phase 3 human trial.
What the researchers studied
MMPOWER-3 randomized 218 people with primary mitochondrial myopathy to elamipretide or placebo. Primary assessments included a six-minute walking test and a disease-specific fatigue score over 24 weeks. Neither primary endpoint was met. [1]
How to interpret the result
The intervention was generally tolerated, but tolerability does not establish efficacy. Findings in mitochondrial myopathy cannot demonstrate anti-aging or general energy-enhancement benefits in healthy adults.
What readers can take from it
Elamipretide is commonly discussed as SS-31. This trial tests clinical outcomes rather than mitochondrial mechanisms alone, and its negative primary findings should remain prominent.
This original editorial summary provides no diagnosis, dosing or treatment advice. The study did not test or certify a PeptiKing product.
Source
[1] Karaa et al., MMPOWER-3 elamipretide trial (2023). PMID: 37268435. Based on the PubMed-indexed abstract and record; full-text methods were not independently reviewed.